Pharmacogenetics: the bioethical problem of DNA investment banking

Studies in History and Philosophy of Science Part C :Studies in History and Philosophy of Biological and Biomedical Sciences

Volumn 37, Issue 3, 2006, Pages 550-565

  Corrigan, Oonagh P ^a   Williams Jones, Bryn ^b  

^a UNIVERSITY OF PLYMOUTH   (United Kingdom)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Clinical drug trials; DNA banking; Informed consent; Pharmacogenetics; Research ethics; Sociological perspective

Indexed keywords

DNA;

ARTICLE; CLINICAL TRIAL; CLINICAL TRIAL (TOPIC); DRUG INDUSTRY; ECONOMICS; ETHICS; GENETICS; HEALTH CARE FACILITY; HUMAN; INFORMED CONSENT; LEGAL ASPECT; PHARMACOGENETICS; RESEARCH ETHICS; RESEARCH SUBJECT; SOCIOECONOMICS;

BIOLOGICAL SPECIMEN BANKS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DNA; DRUG INDUSTRY; ETHICS, RESEARCH; GENETIC RESEARCH; HUMANS; INFORMED CONSENT; PHARMACOGENETICS; RESEARCH SUBJECTS; SOCIOECONOMIC FACTORS;

EID: 33748675942     PISSN: 13698486     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.shpsc.2006.06.004     Document Type: Article

References (63)

1. Andrews L.B., and Nelkin D. Proprietary and property: The tissue market meets the courts. In: Magnus D., Caplan A., and McGee G. (Eds). Who owns life? (2002), Prometheus Books, Amherst, NY 197-222
2. Bamberg M., and Budwig N. Therapeutic misconceptions: When the voices of caring and research are misconstrued as the voice of curing. Ethics and Behaviour 2 3 (1992) 165-184
3. Bergler J., Pennington A., Metcalf M., and Freis E. Informed consent: How much does the patient understand?. Clinical Pharmacology and Therapeutics 27 4 (1980) 435-440
4. Bogdanovic, S., & Langlands, B. (1999). Pharmacogenomics players. BioFrontiers Management Report, Financial Times. London.
5. Boyle J. A theory of information, copyright, spleens, blackmail and insider trading. California Law Review 80 (1992) 1415-1540
6. Brill-Edwards, M. (1999). Canada's health protection branch: whose health, what protection? In M. L. Barer, K. M. McGrail, K. Cardiff, L. Wood, & C. J. Green (Eds.), Tales from other drug wars (pp. 39-54). Vancouver, BC: Centre for Health Services and Policy Research. Papers from the 12th Annual Health Policy Conference, Vancouver, B.C., Nov. 26, 1999. ISBN 0-88865-240-2, p. 42-58 http://www.chspr.ubc.ca/files/publications/2000/12thHPconf.pdf. (Accessed 20 May 2006).
7. Burneo J.G., Montorib V.M., and Faught E. Magnitude of the placebo effect in randomized trials of antiepileptic agents. Epilepsy & Behavior 3 6 (2002) 532-534
8. Cassileth, B., Zupkiss, R., Sutton-Smith, K., & March, V. (1980). Informed consent: Why are its goals imperfectly realized? New England Journal of Medicine, 302(16), 896-900.
9. Corrigan, O. P. (2000). Trial and error: A sociology of bioethics and clinical drug trials, Department of Sociology. Ph.D. Thesis. Essex: University of Essex.
10. Corrigan O.P. Empty ethics: The problem with informed consent. Sociology of Health and Illness 25 3 (2003) 768-792
11. Council for International Organizations of Medical Sciences (1993). International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS. http://www.codex.uu.se/texts/international.html. (Accessed 20 May 2006).
12. Doyal L., and Tobias J. Informed Consent in Medical Research (2001), BMJ Books, London
13. Dresser R. When science offers salvation : Patient advocacy and research ethics (2001), Oxford University Press, Oxford, New York
14. Epstein S. Impure science (1996), University of California Press, London
15. Estey A., Wilkin G., and Dossetor J. Are research subjects able to retain the information they are given during the consent process?. Health Law Review 3 (1994) 37-41
16. Evans, R. G. (1999). Uses and abuses of research and the research process. In M. L. Barer, K. M. McGrail, K. Cardiff, L. Wood, & C. J. Green (Eds.), Tales from the other drug wars. Papers from the 12th Annual Health Policy Conference, Vancouver, BC, Nov. 26, 1999. ISBN 0-88865-240-2. p. 9-20. http://www.chspr.ubc.ca/files/publications/2000/12thHPconf.pdf. (Accessed 20 May 2006).
17. FDA. (1995). FDA consumer special report: Testing drugs in people: http://www.fda.gov/fdac/special/newdrug/testing.html. (Accessed 1 September 2003).
18. Fox R.C. Experiment perilous: forty-five years as a participant observer of patient-orientated clinical research. Perspectives in Biology and Medicine 39 2 (1996) 206-225
19. Gilmour J.M. 'Our' bodies: Property rights in human tissue. Canadian Journal of Law and Society 8 2 (1993) 113-138
20. Glass K.C., and Lemmens T. Conflicts of interest and commercialization of biomedical research. In: Caulfield T., and Williams-Jones B. (Eds). The commercialization of genetic research: Ethical, legal and policy issues (1999), Kluwer Academic/Plenum Press, New York 79-99
21. Greely H.T. Informed consent and other ethical issues in human population genetics. Annual Review of Genetics 35 (2001) 785-800
22. Haimes E. What can the social sciences contribute to the study of ethics? Theoretical, empirical and substantive considerations. Bioethics 16 2 (2002) 89-113
23. Hassar M., and Weintraub M. Uniformed consent and the wealthy volunteer: An analysis of patient volunteers in a clinical trial of a new anti-inflammatory drug. Clinical Pharmacology and Therapeutics 29 (1976) 379-386
24. Horrobin D.F. Innovation in the pharmaceutical industry. Journal of the Royal Society of Medicine 93 7 (2000) 341-345
25. ICH. International Conference for Harmonisation, Good clinical practice, guidance for trials of medicinal products in the European community. In: Foster C. (Ed). Manual for research ethics committees (1998), Kings College, Centre of Medical Ethics and Law, London
26. Jan H., and DeMets D. How informed is informed consent?. Controlled Clinical Trials 2 (1981) 287-303
27. Kent G. The views of members of Local Research Ethics Committees, researchers and members of the public towards the roles and functions of LRECs. Journal of Medical Ethics 23 (1997) 186-190
28. Khan A., Detke M., Khan S.R., and Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. Journal of Nervous and Mental Disease 2003 191 (2003) 4
29. Knoppers B.M., Caulfield T.A., and Kinsella T.D. Legal rights and human genetic material (1996), Emond Montgomery Publications Ltd, Toronto
30. Knoppers B.M. Human genetic material: Commodity or gift?. In: Weir R.F. (Ed). Stored tissues samples: Ethical, legal, and public policy implications (1998), University of Iowa Press, Iowa 226-235
31. Landecker H. Between beneficence and chattel: The human biological in law and science. Science in Context 12 (1999) 203-225
32. Laurie G. Genetic privacy, a challenge to medico-legal norms (2002), Cambridge University Press, Cambridge
33. Lavori P.W., Krause-Steinrauf H., Brophy M., Buxbaum J., Cockroft J., Cox D.R., Fiore L., Greely H.T., Greenberg H., and Holmes E.W. Principles, organization, and operation of a DNA bank for clinical trials: A Department of Veterans Affairs cooperative study. Controlled Clinical Trials 23 3 (2002) 222-239
34. Lemmens T., and Bahamin P. Genetics in life, disability and additional health insurance in Canada: A comparative legal and ethical analysis. In: Knoppers B.M. (Ed). Socio-ethical issues in human genetics (1998), Les Éditions Yvon Blais, Inc., Cowansville, QC 115-275
35. Lewis G. Tissue collection and the pharmaceutical industry: Investigating corporate biobanks. In: Tutton R., and Corrigan O. (Eds). Genetic databases: Socio-ethical issues in the collection and use of DNA (2004), Routledge, London 181-202
36. Lewis S., Baird P.A., Evans R.G., Ghali W.A., Wright C.J., Gibson E., et al. Dancing with the porcupine: Rules for governing the university-industry relationship [commentary]. Canadian Medical Association Journal 165 6 (2001) 783-785
37. MacDonald C., and Williams-Jones B. Ethics and genetics: Susceptibility testing in the workplace. Journal of Business Ethics 35 3 (2002) 235-241
38. Marks A.D., and Steinberg K.K. The ethics of access to online genetic databases: Private or public?. American Journal of Pharmacogenomics 2 3 (2002) 207-212
39. Martin P., and Kaye J. The use of large biological sample collections in genetics research: Issues for public policy. New Genetics & Society 19 2 (2000) 165-191
40. Marx K. Capital: The process of production of capital (1867-1999), Progress Publishers, Moscow, USSR
41. McDonald, M. (2000). The governance of health research involving human subjects (p. xxiv + 363). Ottawa, Ontario: Law Commission of Canada URL http://www.lcc.gc.ca/research_project/health_research-en.asp. (Accessed 20 May 2006).
42. Meek, J. (2002). Decode was meant to save lives ... now it's destroying them, The Guardian, 31 October. London. URL http://www.guardian.co.uk/g2/story/0,3604,822816,00.html. (Accessed 20 May 2006).
43. Merz J., and Sankar P. DNA banking: An empirical study of a proposed consent form. In: Weir R.F. (Ed). Stored tissue samples: Ethical, legal and public policy implications (1998), University of Iowa Press, Iowa 198-225
44. Merz J.F. Discoveries: Are there limits on what may be patented?. In: Magnus D., Caplan A., and McGee G. (Eds). Who Owns Life? (2002), Prometheus Books, Amherst, NY 99-116
45. Mueller M.R. Science versus care: Physicians, nurses and the dilemma of clinical research. In: Elston M.A. (Ed). The sociology of medical science and technology (1997), Blackwell, Oxford 57-78
46. Nathan D.G., and Weatherall D.J. Academic freedom in clinical research. New England Journal of Medicine 347 17 (2002) 1368-1371
47. Nelkin D., and Andrews L.B. Homo economicus: Commercialization of body tissue in the age of biotechnology. Hastings Center Report 28 5 (1998) 30-39
48. O'Neill O. Informed consent and genetic information. Studies in the History and Philosophy of Biological and Biomedical Sciences 32 4 (2001) 689-704
49. Ozdemir V., and Lerer B. Pharmacogenomics and the promise of personalized medicine. In: Kalow W., Meyer U.A., and Tyndale R.F. (Eds). Pharmacogenomics. 2nd ed. (2005), Taylor & Francis, New York 13-50
50. Royal College of Physicians. Research on healthy volunteers (1986), The Royal College of Physicians, London
51. Shafer A. Biomedical conflicts of interest: A defence of the sequestration thesis: Learning from the cases of Nancy Olivieri and David Healy. Journal of Medical Ethics 30 1 (2004) 8-24
52. Snowdon C., Garcia J., and Elbourne D. Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial. Social Science and Medicine 45 (1997) 1337-1355
53. Specter, M. (1999). Decoding Iceland, The New Yorker, 18 January (pp. 40-51).
54. Steflox H.T., Chua G., O'Rourke K., and Detsky A.S. Conflict of interest in the debate over calcium channel antagonists. New England Journal of Medicine 338 2 (1998) 101-106
55. Taylor K.M. Telling bad news: Physicians and the disclosure of undesirable information. Sociology of Health and Illness 10 (1988) 109-132
56. van den Haak, M. (2001). Fewer new launches in 2000, CMR International News, 19(1), 10-14. URL http://www.cmr.org/pdf/april2001.pdf. (Accessed 20 May 2006).
57. Waldby C. The Visible Human Project: Informatic bodies and posthuman medicine (2000), Routledge, New York and London
58. Webster A., Martin P., Lewis G., and Smart A. Integrating pharmacogenetics into society: In search of a model. Nature Reviews Genetics 5 9 (2004) 663-669
59. Weijer C. The ethical analysis of risk. Journal of Law, Medicine & Ethics 28 (2000) 344-361
60. Wilkinson M., and Moore A. Inducement in research. Bioethics 11 5 (1997) 373-389
61. Williams-Jones B., and Corrigan O.P. Rhetoric and hype: Where's the "ethics" in pharmacogenomics?. American Journal of Pharmacogenomics 3 6 (2003) 375-383
62. Williams-Jones B., and Holm S. A university wide model for the ethical review of human subjects research. Research Ethics Review 1 2 (2005) 39-44
63. World Medical Association (2000). Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/b3.htm. (Accessed 20 May 2006).